Journal of Clinical Endocrinology & Metabolism, Vol 64, 557-562, Copyright © 1987 by Endocrine Society

ARTICLES

Dihydrotestosterone heptanoate: synthesis, pharmacokinetics, and effects on hypothalamic-pituitary-testicular function

BS Keenan, AJ Eberle, JT Sparrow, NG Greger and WB Panko

Dihydrotestosterone heptanoate (DHT-hp), a seven-carbon fatty acid ester of DHT, was synthesized, and its pharmacokinetics and effects on hypothalamic-pituitary-testicular function were determined in men and pubertal boys. Plasma DHT levels markedly increased 24 h after im injection of DHT-hp, reached their peak during the first week, and fell to baseline levels after 4-6 weeks. An estimated 43-55% of DHT-hp was converted to DHT 4-6 weeks after injection. Plasma testosterone, estradiol, LH, and FSH levels decreased by 4 days after DHT-hp injection, were lowest during the second week, and returned to baseline values after 4-6 weeks. The LH and FSH responses to GnRH were diminished by chronic administration of DHT-hp to pubertal boys at 3- week intervals for 15 weeks. The affinity of DHT-hp was 100 times less than the affinity of DHT for the human androgen receptor, and no affinity for the estrogen receptor in breast tissue could be demonstrated. Since DHT is a nonaromatizable androgen, and neither DHT nor DHT-hp binds readily to the estrogen receptor, suppression of LH and FSH secretion by this drug probably occurs via an androgen- dependent mechanism. Receptor binding and pharmacokinetic data indicate that unesterified DHT is the active principle. DHT-hp is a useful derivative of DHT, since prompt, predictable, and sustained rises in DHT occur after its administration.

This article has been cited by other articles:

				C. Wang and R. S. Swerdloff Should the Nonaromatizable Androgen Dihydrotestosterone Be Considered as an Alternative to Testosterone in the Treatment of the Andropause? J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1462 - 1466. [Full Text] [PDF]

				R. J. Saad, B. S. Keenan, K. Danadian, V. D. Lewy, and S. A. Arslanian Dihydrotestosterone Treatment in Adolescents with Delayed Puberty: Does it Explain Insulin Resistance of Puberty? J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4881 - 4886. [Abstract] [Full Text] [PDF]

				L. P. Ly, M. Jimenez, T. N. Zhuang, D. S. Celermajer, A. J. Conway, and D. J. Handelsman A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Transdermal Dihydrotestosterone Gel on Muscular Strength, Mobility, and Quality of Life in Older Men with Partial Androgen Deficiency J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4078 - 4088. [Abstract] [Full Text] [PDF]

				C. Wang, A. Iranmanesh, N. Berman, V. McDonald, B. Steiner, F. Ziel, S. M. Faulkner, R. E. Dudley, J. D. Veldhuis, and R. S. Swerdloff Comparative Pharmacokinetics of Three Doses of Percutaneous Dihydrotestosterone Gel in Healthy Elderly Men-A Clinical Research Center Study J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2749 - 2757. [Abstract] [Full Text]

				S. B. Coutts, A. T. Kicman, D. T. Hurst, and D. A. Cowan Intramuscular administration of 5{alpha}-dihydrotestosterone heptanoate: changes in urinary hormone profile Clin. Chem., November 1, 1997; 43(11): 2091 - 2098. [Abstract] [Full Text] [PDF]